SOD1 and allergic rhinitis: In conclusion, by analysing two pharmacological treatments with clemastine in SOD1-G93A mice, one up to symptomatic phase and the other up to the end stage of the disease, we have gained insights into the ameliorating actions of an antihistaminergic compound in ALS progression and repositioned clemastine from a drug for allergic rhinitis to a potential pharmacological compound for ALS.